Zacks Investment Research upgraded shares of Akari Therapeutics PLC (NASDAQ:AKTX) from a sell rating to a hold rating in a research report report published on Monday morning.

According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “

AKTX has been the subject of a number of other reports. Chardan Capital reiterated a neutral rating on shares of Akari Therapeutics PLC in a research report on Sunday, September 17th. William Blair upgraded shares of Akari Therapeutics PLC from a market perform rating to an outperform rating in a research report on Friday, September 22nd. Canaccord Genuity reiterated a buy rating and issued a $15.00 target price on shares of Akari Therapeutics PLC in a research report on Friday, September 22nd. Finally, ValuEngine upgraded shares of Akari Therapeutics PLC from a strong sell rating to a sell rating in a research report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. Akari Therapeutics PLC currently has a consensus rating of Hold and an average target price of $8.00.

Shares of Akari Therapeutics PLC (AKTX) traded down $0.02 during midday trading on Monday, hitting $4.46. 101,500 shares of the stock were exchanged, compared to its average volume of 383,638. Akari Therapeutics PLC has a 1-year low of $3.18 and a 1-year high of $22.20.

ILLEGAL ACTIVITY NOTICE: “Akari Therapeutics PLC (AKTX) Upgraded to “Hold” at Zacks Investment Research” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/14/akari-therapeutics-plc-aktx-upgraded-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Akari Therapeutics PLC stock. Hikari Power Ltd boosted its stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,334 shares of the biopharmaceutical company’s stock after buying an additional 91,322 shares during the quarter. Hikari Power Ltd owned 1.28% of Akari Therapeutics PLC worth $929,000 as of its most recent SEC filing. 26.97% of the stock is owned by institutional investors and hedge funds.

About Akari Therapeutics PLC

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.